Table 1.
Jumping translocation (JT) cohorts in this study
| JT Type | Data Source (age, sex) | Disease | Total | Pre-JT* Karyotype “N” for normal and “A” for abnormal karyotype |
Jumping Translocation (JT) Karyotype | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Recipient chromosomes involved in JT*** In the number of patients |
Extra chromosomal abnormalities besides JT*** | |||||||||||||||
| Acrocentric Chromosome (p arms) | Telomeric Region | Centromeric Region | Other Region | 0 | 1 | 2 | ≥ 3 | |||||||||
| 13p | 14p | 15p | 21p | 22p | ||||||||||||
| 1q-JT | JH cohort, median age 76 (46–88 yrs), 11 M / 10 F | AML | 14 | 7 N / 3 A | 6 | 5 | 9 | 5 | 6 | 2 (1p, 7q, 18p, 18q) | 2 (16q) | 0 | 6 | 5 | 2 | 1 |
| MDS | 4 | 1 N | 1 | 1 | 1 | 0 | 1 | 3 (2q, 7q, 18q) | 2 (16q) | 0 | 1 | 3 | 0 | 0 | ||
| MDS -> AML | 2 | 2 N | 2 | 0 | 0 | 0 | 1 | 0 | 1 (Yq) | 0 | 1 | 1 | 0 | 0 | ||
| MPN | 1 | NA | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | ||
| MD Anderson cohort, median age 66 (43–90 yrs), 14 M / 4 F | AML | 3 | 2 N / 1 A | 1 | 2 | 2 | 1 | 0 | 1 (7p, 9q) | 2 (Yq, 7p) | 1 | 2 | 1 | 0 | 0 | |
| CMML -> AML | 3 | 3 N | 1 | 3 | 3 | 1 | 0 | 2 (4q, Yq) | 3 (Yq, 9p/q, 16p, 18q) | 0 | 1 | 0 | 2 | 0 | ||
| MDS | 6 | 2 N / 1 A | 4 | 3 | 1 | 3 | 1 | 3 (4q, 5q, 18q) | 4 (Yq, 5p, 7p, 12p, 16p/q, 19p) | 2 | 3 | 0 | 1 | 2 | ||
| MDS / T-MDS -> AML | 4 | 1 N / 2 A | 3 | 3 | 2 | 1 | 1 | 2 (6q, 7q) | 1 (Yp) | 2 | 3 | 0 | 1 | 0 | ||
| MPN | 1 | 1 N | 0 | 0 | 1 | 0 | 0 | 0 | 1 (7p, 9p) | 0 | 1 | 0 | 0 | 0 | ||
| MPN -> blast phase | 1 | 1 A | 1 | 0 | 1 | 0 | 1 | 1 (8p, 17p) | 1 (20p) | 0 | 0 | 0 | 1 | 0 | ||
| Total number of patients | 39 | 19 N / 8 A | 20 | 19 | 20 | 12 | 11 | 14 | 17 | 5 | 19 | 10 | 7 | 3 | ||
| Non 1q-JT** | MD Anderson cohort, median age 43 (40–46 yrs), 3 M / 4 F | AML | 4 | 4 N | 0 | 0 | 0 | 1 | 0 | 3 (1q, 6p/q, 9q, 10q, 12q, 13q, 14q, 16p) | 1 (16p, 17q, 18p) | 3 | 4 | 0 | 0 | 0 |
| AML -> AML w/ MRC | 2 | 2 A | 0 | 0 | 0 | 0 | 0 | 2 (5q, 6p, 11p, 17q) | 0 | 1 | 2 | 0 | 0 | 0 | ||
| CMML -> AML | 1 | 1 N | 0 | 0 | 0 | 0 | 0 | 1 (9q, 20q) | 0 | 1 | 0 | 1 | 0 | 0 | ||
| Total number of patients | 7 | 5 N / 2 A | 0 | 0 | 0 | 1 | 0 | 6 | 1 | 5 | 6 | 1 | 0 | 0 | ||
*The majority of pre-JT specimens had normal karyotypes (approximately 71%). **Non-1q JT cases involved bands of 1p22, 1q25, 3q21, 7p15, 12p13, 15q21, and 21q22, all of which involved telomeric regions as recipient chromosomes. Receipt chromosomes in non-1q JT were different from these in 1q-JT. The majority of receipt chromosomes in 1q-JT involved in the short arms of acrocentric chromosomes (approximately 70%). ***Acrocentric Chromosomes, “Telomeric Regions”, “Centromeric Regions”, “Other Regions”, and “Extra chromosomal abnormalities besides JT” refer to the number of patients. A = Abnormal karyotype; N = Normal karyotype; NA = Data not available; yrs = years. AML: acute myeloid leukemia; AML w/MRC: acute myeloid leukemia with myelodysplasia related changes; CMML: chronic myelomonocytic leukemia; F: female; JT: jumping translocation; M: male; MDS: myelodysplastic syndrome; MPN: myeloproliferative neoplasm; T-MDS: treatment-related myelodysplastic syndrome.